Early safety check for new chikungunya drug
NCT ID NCT04441905
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a single dose of an experimental drug called SAR440894 in 42 healthy adults to see if it was safe. The goal was not to treat the disease but to gather initial safety information before testing it in people with chikungunya virus infection. Participants were monitored for side effects over about 150 days.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHIKUNGUNYA VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Duke University School of Medicine - Duke Clinical Research Institute - Duke Clinical Research Unit
Durham, North Carolina, 27710, United States
-
PPD - Austin Clinical Research Unit
Austin, Texas, 78744-1645, United States
-
Pharmaceutical Product Development - Orlando Clinical Research Unit
Orlando, Florida, 32806, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single shot shield children from chikungunya?
- Chikungunya Vaccine's Long-Term shield put to the test
- New rapid test could speed up tropical fever diagnosis
- Chikungunya vaccine safety checked in pregnant women
- New chikungunya vaccine enters first human safety trial
- Brazilian pilot program tests chikungunya Vaccine's Real-World power